NewsGlobeNewswire
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
· Published
Article summary
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…